How hepatitis C virus counteracts the interferon response: The jury is still out on NS5A

被引:152
作者
Tan, SL
Katze, MG
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Infect Dis Res, Indianapolis, IN 46285 USA
[2] Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA
[3] Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA
关键词
hepatitis C virus; interferon; E2; NS5A; PKR; JAK-STAT pathway;
D O I
10.1006/viro.2001.0885
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Interferons (IFNs) induce an antiviral state in the cell through complex and indirect mechanisms, which culminate in a direct inhibition of viral replication and stimulation of the host adaptive responses. Viruses often counteract with elaborate strategies to interfere with the induction as well as action of IFN effector molecules. This evolutionary battle between viruses and IFN components is a subject of intense research aimed at understanding the immunopathogenesis of viruses and the molecular basis of IFN signaling and action. In the case with hepatitis C virus (HCV), this may have profound implications for the therapeutic use of recombinant IFN in treating chronic hepatitis C. Depending on the subtype of HCV, current IFN-based treatment regimens are effective for only a small subset of chronic hepatitis C patients. Thus, one of the Holy Grails in HCV research is to understand the mechanisms by which the virus may evade IFN antiviral surveillance and establish persistent infection, which may eventually provide insights into new avenues for better antiviral therapy. Despite the lack of an efficient tissue culture system and an appropriate animal model for HCV infection, several mechanisms have been proposed based on clinical studies and in vitro experiments. This minireview focuses on the HCV NS5A nonstructural protein. which is implicated in playing a role in HCV tolerance to IFN treatment, possibly in part through its ability to inhibit the cellular IFN-induced PKR protein kinase. (C) 2001 Academic Press.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 114 条
[1]   Suppression of interferon-induced antiviral activity in cells expressing hepatitis C virus proteins [J].
Aizaki, H ;
Saito, S ;
Ogino, T ;
Miyajima, N ;
Harada, T ;
Matsuura, Y ;
Miyamura, T ;
Kohase, M .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2000, 20 (12) :1111-1120
[2]   Viral mechanisms of immune evasion [J].
Alcami, A ;
Koszinowski, UH .
TRENDS IN MICROBIOLOGY, 2000, 8 (09) :410-418
[3]   The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[4]  
ARIME N, 2001, IN PRESS J BIOL CHEM
[5]   Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/caspase-8 death signaling pathway [J].
Balachandran, S ;
Roberts, PC ;
Kipperman, T ;
Bhalla, KN ;
Compans, RW ;
Archer, DR ;
Barber, GN .
JOURNAL OF VIROLOGY, 2000, 74 (03) :1513-1523
[6]   The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-α [J].
Barnard, P ;
McMillan, NAJ .
VIROLOGY, 1999, 259 (02) :305-313
[7]   Replication of hepatitis C virus [J].
Bartenschlager, R ;
Lohmann, V .
JOURNAL OF GENERAL VIROLOGY, 2000, 81 :1631-1648
[8]   Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection [J].
Battaglia, AM ;
Hagmeyer, KO .
ANNALS OF PHARMACOTHERAPY, 2000, 34 (04) :487-494
[9]   Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment [J].
Berg, T ;
Marques, AM ;
Höhne, M ;
Wiedenmann, B ;
Hopf, U ;
Schreier, E .
HEPATOLOGY, 2000, 32 (06) :1386-1395
[10]   Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha [J].
Bhattacharya, S ;
Eckner, R ;
Grossman, S ;
Oldread, E ;
Arany, Z ;
DAndrea, A ;
Livingston, DM .
NATURE, 1996, 383 (6598) :344-347